Barclays analyst Peter Lawson raised the firm’s price target on Exelixis (EXEL) to $29 from $25 and keeps an Equal Weight rating on the shares following the Q4 report. The firm says the cabozantinib franchise sales are in line with the early 2025 preannouncement. The focus is on the potential FDA approval and commercial launch in neuroendocrine tumors with updated sales guidance expected post approval, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $38 from $37 at Piper Sandler
- Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
- Exelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug Developments
- Exelixis price target raised to $45 from $38 at Citi
- Positive Outlook for Exelixis Driven by Promising Developments in Zanzalintinib and Cabozantinib